We are live on ! Find out more
TNXP icon

Tonix Pharmaceuticals
TNXP

12 hedge funds and large institutions have $52M invested in Tonix Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

909% more capital invested

Capital invested by funds: $5.16M → $52M (+$46.9M)

700% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 1

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

140% more funds holding

Funds holding: 5 → 12 (+7)

0% more ownership

Funds ownership: 0% → 0% (+0%)

Holders
12
Holders Change
+7
Holders Change %
+140%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
3
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$15.3M
2
Renaissance Technologies
Renaissance Technologies
New York
+$9.94M
3
BlackRock
BlackRock
New York
+$7.65M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$3.06M
5
Millennium Management
Millennium Management
New York
+$1.53M

Top Sellers

Rank Fund Capital Flow
1
GCP
GSA Capital Partners
United Kingdom
-$765K
2
Squarepoint
Squarepoint
New York
-$459K
3
N
Natixis
France
-$36K
4
RFA
Reilly Financial Advisors
California
-$17K
5
LFG
Larson Financial Group
Missouri
-$14K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$18.8M +$15.3M +20 +667%
Renaissance Technologies
2
Renaissance Technologies
New York
$10.8M +$9.94M +13 New
BlackRock
3
BlackRock
New York
$9.73M +$7.65M +10 +500%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$3.71M +$3.06M +4 +400%
Millennium Management
5
Millennium Management
New York
$1.26M +$1.53M +2 New
Susquehanna International Group
6
Susquehanna International Group
Pennsylvania
$1.01M +$765K +1 New
Northern Trust
7
Northern Trust
Illinois
$813K +$765K +1 New
Citadel Advisors
8
Citadel Advisors
Florida
$776K +$765K +1 New
ECM
9
ExodusPoint Capital Management
New York
$762K +$765K +1 New
GCP
10
GSA Capital Partners
United Kingdom
$554K -$765K -1 -50%
LP
11
LMR Partners
United Kingdom
$500K +$765K +1 New
HF
12
HRT Financial
New York
$445K +$765K +1 New
Morgan Stanley
13
Morgan Stanley
New York
$361K – – –
BCM
14
Bridgeway Capital Management
Texas
$339K – – –
Goldman Sachs
15
Goldman Sachs
New York
$322K – – –
First Trust Advisors
16
First Trust Advisors
Illinois
$279K – – –
Bank of New York Mellon
17
Bank of New York Mellon
New York
$210K – – –
Charles Schwab
18
Charles Schwab
California
$162K – – –
EDRH
19
Edmond de Rothschild Holding
Switzerland
$128K – – –
EMG
20
ETF Managers Group
New Jersey
$125K – – –
State Street
21
State Street
Massachusetts
$99K – – –
Capstone Investment Advisors
22
Capstone Investment Advisors
New York
$73K – – –
Victory Capital Management
23
Victory Capital Management
Texas
$67K – – –
JG
24
Jefferies Group
New York
$58.2K – – –
Balyasny Asset Management
25
Balyasny Asset Management
Illinois
$45K – – –
1
2 3

TNXP Hedge Fund Activity: Q1 2021 in Review

12 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Tonix Pharmaceuticals (TNXP) for Q1 2021, worth a combined $52M — up 909% from $5.16M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new TNXP positions and 1 closed out — a net gain of 7 holders — while 3 added to existing stakes and 1 trimmed.

The largest buyer was Vanguard Group, adding an estimated $15.3M. The largest seller was GSA Capital Partners, cutting an estimated $765K.

  • 12 institutional investors held Tonix Pharmaceuticals (TNXP) as of Q1 2021, up from 5 in Q4 2020.
  • Funds reported $52M of Tonix Pharmaceuticals stock for Q1 2021, up 909% quarter-over-quarter.
  • 8 funds opened new Tonix Pharmaceuticals positions in Q1 2021 and 1 closed out, a net change of +7 holders.
  • The largest Tonix Pharmaceuticals buyer in Q1 2021 was Vanguard Group, an estimated $15.3M added.
  • The largest Tonix Pharmaceuticals seller in Q1 2021 was GSA Capital Partners, an estimated $765K sold.

Based on aggregated 13F filings for Q1 2021.